SHILPA MEDICARE Q2 FY27 CONCALL: TARGETS PEPTIDE CAPACITY COMMISSIONING BY FY27-END, ROTIGOTINE & TWO OTHER PRODUCT LAUNCHES IN FY28; FOUR CDMO PROGRAMS TO COMMERCIALISE OVER 18–24 MONTHS, 15+ ONCOLOGY PRODUCTS & SEMAGLUTIDE FILING ON TRACK